Effect of Body Composition Change during Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma

被引:6
作者
Onishi, Sachiyo [1 ]
Tajika, Masahiro [1 ]
Tanaka, Tsutomu [1 ]
Yamada, Keisaku [1 ]
Kamiya, Tomoyasu [1 ]
Abe, Tetsuya [2 ]
Higaki, Eiji [2 ]
Fujieda, Hironori [2 ]
Nagao, Takuya [2 ]
Inaba, Yoshitaka [3 ]
Muro, Kei [4 ]
Shimizu, Masahito [5 ]
Niwa, Yasumasa [1 ]
机构
[1] Aichi Canc Ctr Hosp, Dept Endoscopy, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan
[2] Aichi Canc Ctr Hosp, Dept Surg Gastroenterol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan
[3] Aichi Canc Ctr Hosp, Dept Diagnost & Intervent Radiol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan
[4] Aichi Canc Ctr Hosp, Dept Clin Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan
[5] Gifu Univ, Grad Sch Med, Dept Gastroenterol Internal Med, 1-1 Yanagido, Gifu 5011194, Japan
关键词
esophageal squamous cell carcinoma; neoadjuvant chemotherapy; sarcopenia; SKELETAL-MUSCLE MASS; PULMONARY COMPLICATIONS; PSOAS MUSCLE; SARCOPENIA; CANCER; OUTCOMES; PREDICTOR; NUTRITION; MORTALITY; IMPACT;
D O I
10.3390/jcm11030508
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Effects of changes in body composition during neoadjuvant chemotherapy (NAC) on perioperative complications and prognosis are unknown in patients with esophageal squamous cell carcinoma (ESCC). A total of 175 patients who underwent surgery for ESCC in our hospital between 2016 and 2019 were examined. The psoas muscle index (PMI) was calculated from the total psoas muscle area, and the visceral fat mass (VFM) at the umbilical level was measured. We defined body composition change (BCC) group as those with increased VFM of >= 3% and decreased PMI of >= 3% during NAC. Sarcopenia (S) was defined as PMI < 5.89 (male) and <4.06 (female). Nutritional assessment using the Subjective Global Assessment tool was performed upon admission. The percentages of BCC group, pre-NAC S, and post-NAC S was 32.5%, 79.4%, and 80.0%, respectively. BCC group had significantly more postoperative complications (p < 0.01) and longer hospital stays (p = 0.03) than groups pre-NAC S and post-NAC S. Overall survival (OS) analysis using the Cox hazard model showed that stage III (p < 0.01) and post-NAC S (p = 0.03) were poor prognostic factors. Changes in body composition during NAC affected perioperative complications and prognosis of patients with ESCC.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Circulating tumor cells after neoadjuvant chemotherapy are related with recurrence in esophageal squamous cell carcinoma
    Daisuke Ujiie
    Takuro Matsumoto
    Eisei Endo
    Hirokazu Okayama
    Shotaro Fujita
    Yasuyuki Kanke
    Yohei Watanabe
    Hiroyuki Hanayama
    Suguru Hayase
    Zenichirou Saze
    Shinji Ohki
    Koji Kono
    Esophagus, 2021, 18 : 566 - 573
  • [32] Neoadjuvant PD-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
    Qian, Ting
    Liu, Delin
    Cao, Guochun
    Chen, Zhipeng
    Zhang, Qin
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
  • [33] Therapeutic value of lymph node dissection for esophageal squamous cell carcinoma after neoadjuvant chemotherapy
    Miyata, Hiroshi
    Yamasaki, Makoto
    Makino, Tomoki
    Miyazaki, Yasuhiro
    Takahashi, Tsuyoshi
    Kurokawa, Yukinori
    Nakajima, Kiyokazu
    Takiguchi, Shuji
    Mori, Masaki
    Doki, Yuichiro
    JOURNAL OF SURGICAL ONCOLOGY, 2015, 112 (01) : 60 - 65
  • [34] Circulating tumor cells after neoadjuvant chemotherapy are related with recurrence in esophageal squamous cell carcinoma
    Ujiie, Daisuke
    Matsumoto, Takuro
    Endo, Eisei
    Okayama, Hirokazu
    Fujita, Shotaro
    Kanke, Yasuyuki
    Watanabe, Yohei
    Hanayama, Hiroyuki
    Hayase, Suguru
    Saze, Zenichirou
    Ohki, Shinji
    Kono, Koji
    ESOPHAGUS, 2021, 18 (03) : 566 - 573
  • [35] Multiple diffusion models for predicting pathologic response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy
    Bai, Bingmei
    Cui, Long
    Chu, Funing
    Wang, Zhaoqi
    Zhao, Keke
    Wang, Shuting
    Wang, Shaoyu
    Yan, Xu
    Wang, Mengzhu
    Kamel, Ihab R.
    Yang, Guang
    Qu, Jinrong
    ABDOMINAL RADIOLOGY, 2024, 49 (12) : 4216 - 4226
  • [36] The Immunological Impact of Neoadjuvant Chemotherapy on the Tumor Microenvironment of Esophageal Squamous Cell Carcinoma
    Takahiro Tsuchikawa
    Masaki Miyamoto MD
    Yoshiyuki Yamamura
    Toshiaki Shichinohe
    Satoshi Hirano
    Satoshi Kondo
    Annals of Surgical Oncology, 2012, 19 : 1713 - 1719
  • [37] Significance of lymphovascular invasion in esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy
    Oguma, Junya
    Ishiyama, Koshiro
    Kurita, Daisuke
    Kanematsu, Kyohei
    Kubo, Kentaro
    Utsunomiya, Daichi
    Yamamoto, Shun
    Honma, Yoshitaka
    Kato, Ken
    Daiko, Hiroyuki
    ESOPHAGUS, 2023, 20 (02) : 215 - 224
  • [38] Prognostic Factors for Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery
    Kitasaki, Nao
    Hamai, Yoichi
    Emi, Manabu
    Kurokawa, Tomoaki
    Yoshikawa, Toru
    Hirohata, Ryosuke
    Ohsawa, Manato
    Okada, Morithito
    IN VIVO, 2022, 36 (06): : 2852 - 2860
  • [39] Neoadjuvant treatment for esophageal squamous cell carcinoma
    Baba, Yoshifumi
    Watanabe, Masayuki
    Yoshida, Naoya
    Baba, Hideo
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2014, 6 (05) : 121 - 128
  • [40] Short-term Outcomes of Adjuvant Nivolumab After Neoadjuvant Chemotherapy in Patients With Resected Esophageal Squamous Cell Carcinoma
    Sugase, Takahito
    Kanemura, Takashi
    Takeoka, Tomohira
    Matsuura, Norihiro
    Masuike, Yasunori
    Shinno, Naoki
    Hara, Hisashi
    Kitakaze, Masatoshi
    Kubo, Masahiko
    Mukai, Yosuke
    Sueda, Toshinori
    Hasegawa, Shinichiro
    Akita, Hirofumi
    Nishimura, Junichi
    Wada, Hiroshi
    Yasui, Masayoshi
    Omori, Takeshi
    Miyata, Hiroshi
    ANTICANCER RESEARCH, 2024, 44 (01) : 185 - 193